Holen Sie sich die Stockscreener-App
107.99
0.19%
-0.3168
Schlusskurs vom Vortag:
$108.31
Offen:
$107.67
24-Stunden-Volumen:
109.01K
Relative Volume:
0.06
Marktkapitalisierung:
$12.23B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$348.84M
KGV:
38.84
EPS:
2.7805
Netto-Cashflow:
$667.65M
1W Leistung:
-1.42%
1M Leistung:
+4.84%
6M Leistung:
+58.65%
1J Leistung:
+42.11%
1-Tages-Spanne:
$106.83
$108.79
1-Wochen-Bereich:
$106.07
$111.15
52-Wochen-Spanne:
$61.23
$111.15
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Firmenname
Halozyme Therapeutics Inc
Sektor
Branche
Telefon
(858) 794-8889
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
107.78 | 12.29B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
522.04 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
799.73 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.54 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.27 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Herabstufung | Goldman | Neutral → Sell |
| 2025-10-14 | Hochstufung | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-05-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Herabstufung | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Eingeleitet | TD Cowen | Outperform |
| 2023-07-24 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Berenberg | Buy |
| 2023-03-16 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Eingeleitet | Evercore ISI | Outperform |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Bestätigt | The Benchmark Company | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Fortgesetzt | Piper Jaffray | Neutral |
| 2018-05-11 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2017-10-16 | Bestätigt | Piper Jaffray | Overweight |
| 2017-01-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-11-18 | Eingeleitet | Citigroup | Buy |
| 2015-09-22 | Eingeleitet | Barclays | Overweight |
| 2015-06-22 | Bestätigt | JP Morgan | Overweight |
| 2015-03-03 | Bestätigt | UBS | Buy |
| 2015-02-18 | Bestätigt | MLV & Co | Buy |
| 2015-01-08 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Halozyme Therapeutics (NASDAQ:HALO) Screens Well on High Growth Momentum and Breakout Setup - ChartMill
Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now? - Zacks Investment Research
Biotech Stocks At 52-Week HighsATTO, HALO, IKT, TVTX, ATRC - RTTNews
Halozyme Therapeutics stock hits all-time high at 109.69 USD By Investing.com - Investing.com Nigeria
Halozyme (NASDAQ: HALO) awards board member new RSUs and options vesting at 2027 meeting - Stock Titan
Halozyme Therapeutics stock hits all-time high at 109.69 USD - Investing.com
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $115 - Moomoo
Halozyme Investor Conferences Put ENHANZE and Expanded Drug Delivery Portfolio in Focus - Yahoo Finance
Halozyme to Participate at Upcoming Investor Conferences - marketscreener.com
Three Halozyme executive talks will be webcast in September - Stock Titan
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Halozyme: The Market May Be Underpricing The Second Growth Wave (NASDAQ:HALO) - Seeking Alpha
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Robust Growth Trajectory in the Biotech Sector - DirectorsTalk Interviews
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice - Eastern Progress
Halozyme Therapeutics (HALO) Stock Trades At A Premium To Fair Value - Yahoo Finance
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Eastern Progress
Halozyme Therapeutics stock hits all-time high at 109.59 USD By Investing.com - Investing.com Nigeria
Halozyme Therapeutics stock hits all-time high at 109.59 USD - Investing.com
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Strong Revenue Growth and Robust Pipeline Drive Investor Interest - DirectorsTalk Interviews
Halozyme (HALO) Stock Could Be Fully Priced On The Board Appointment - Sahm
New Halozyme (NASDAQ: HALO) director logs zero stock in first ownership filing - Stock Titan
HALO Stock Rises 36% in a Month: Here's What You Should Know - TradingView
Great Lakes Advisors LLC Purchases Shares of 36,039 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HALO) Adds A New Director, Is It 21% Overvalued? - Sahm
Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme CEO Helen Torley sells $6.28m in company shares By Investing.com - Investing.com Australia
Halozyme CEO Helen Torley sells $6.28m in company shares - Investing.com
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock - MarketBeat
Halozyme (NASDAQ: HALO) CEO sells tens of thousands of shares - Stock Titan
Halozyme (HALO) Levels: Moves 2.60% Up to $107.62 in the Latest Reading; Range View: Price Remains Between $102.24 Support and $113.00 Resistance for the Current SessionInsider Buying Alerts - Vinanet
Halozyme Appoints Dannielle Appelhans to Board of Directors - The Globe and Mail
Foster & Motley Inc. Invests $2 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Diversify Advisory Services LLC Invests $2.77 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics(HALO.US) Officer Sells US$6.28 Million in Common Stock - Moomoo
Halozyme Therapeutics Appoints Dannielle Appelhans to Board of Directors - Kalkine Media
Halozyme Therapeutics (NASDAQ:HALO): What Is Driving the Rally? - Kalkine Media
Halozyme adds Dannielle Appelhans to board of directors - Investing.com
Halozyme adds Dannielle Appelhans to board of directors By Investing.com - Investing.com Australia
Halozyme Therapeutics stock hits all-time high of 104.86 USD By Investing.com - Investing.com Australia
Halozyme Appoints Dannielle Appelhans to its Board of Directors - PR Newswire
Halozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week HighWhat's Next? - MarketBeat
Halozyme Therapeutics stock hits all-time high of 104.86 USD - Investing.com
H.C. Wainwright reiterates Halozyme stock rating on partner data By Investing.com - Investing.com Canada
HALO Q2 2026 Earnings: EPS Surges 21.75% Above Estimates, Shares Climb 4.4%New Analyst Coverage - Vinanet
Halozyme (NASDAQ: HALO) insider lines up new stock sale after recent disposals - Stock Titan
Horizon Investment Services LLC Buys Shares of 28,793 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth - DirectorsTalk Interviews
Chase Investment Counsel Corp Buys New Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call - Yahoo Finance
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics? - Yahoo Finance
Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Halozyme Therapeutics Inc-Aktie (HALO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Aug 18 '26 |
Option Exercise |
18.41 |
20,000 |
368,200 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
Aug 19 '26 |
Option Exercise |
18.41 |
20,000 |
368,200 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
Aug 19 '26 |
Sale |
107.00 |
20,000 |
2,139,976 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Aug 18 '26 |
Sale |
104.18 |
20,000 |
2,083,525 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Aug 17 '26 |
Sale |
102.60 |
20,000 |
2,052,091 |
767,780 |
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):